Summary
Recipharm AB (Recipharm) a subsidiary of B&E Participation AB is a contract development and manufacturing organization that offers a wide range of services to pharmaceutical companies. The organization operates business in two reportable segments that include manufacturing, and development and technology. Its manufacturing segment provides contract manufacturing of pharmaceuticals in a wide range of forms including semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial material including APIs and other drugs. Recipharm’s Development & Technology segment offers services that include raw material supply, formulation development and development of validated analytical methods, and among others. The organization also operates in the UK, Germany, Spain, Italy, Sweden, France, and others. Recipharm is headquartered in Jordbro, Sweden.
Recipharm AB (RECI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Recipharm AB, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Recipharm AB, Medical Devices Deals, 2010 to YTD 2016 12
Recipharm AB, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Recipharm AB, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 15
Recipharm Acquires Manufacturing Site From Abbott Labs 17
Partnerships 18
Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 18
Recipharm Enters into Agreement with Follicum 19
Recipharm Enters into Agreement with Synthonics 20
Recipharm Enters Into Co-Promotion Agreement With Synthonics 21
KAHR medical Enters Into An Agreement With RecipharmCobra For KAHR-102 22
Mylan Enters Into Co-Marketing Agreement With Edmond Pharma 23
Orion Enters Into Distribution Agreement With Edmond Pharma For Erdotin 24
Licensing Agreements 25
Alitair Pharma And Edmond Pharma Enter Into Licensing Agreement For Erdosteine 25
iNova Pharma (Australia) Enters Into Licensing Agreement With Edmond Pharma For Erdosteine 27
Life Technologies Enters Into Licensing Agreement With RecipharmCobra Biologics 29
Eddingpharm Enters Into License Agreement With Edmond Pharma For Erdotin 30
MegaPharm Enters Into Licensing Agreement With Edmond Pharma For Erdotin 31
Rottapharm Madaus Enters Into Licensing Agreement With Edmond Pharma For Mucodox 32
Equity Offering 33
Recipharm to Raise up to USD104.5 Million in Rights Offering of Shares 33
Recipharm to Raise USD15.5 Million in Private Placement of Class B Shares 35
Recipharm Raises USD32 Million in Private Placement of Shares 36
Synthonics Raises USD2 Million in Private Placement of Preferred Shares 38
Flamel to Raise USD13.1 Million in Private Placement of Shares 39
Recipharm Announces Underwriters Exercise Of Over-Allotment Option Of IPO For US$131.37 Million 41
Recipharm Completes Private Placement Of Shares For US$29 Million 42
Asset Transactions 43
Oxford BioMedica To Acquire GMP Manufacturing Facility From Recipharm 43
Acquisition 45
Recipharm to Acquire Kemwell Biopharma 45
Recipharm Acquires 74% Stake in Nitin Lifesciences for USD101 Million 47
Recipharm Italia Acquires Mitim for USD75 Million 49
Recipharm Acquires Kaysersberg Pharma from Alcon for USD16.6 Million 50
Recipharm Acquires OnTarget Chemistry for USD1.8 Million 52
Recipharm Acquires Lusomedicameta Sociedade for USD135 Million 53
Recipharm Acquires Corvette Pharma Services from LBO Italia Investimenti for USD160 Million 54
Corvette Group Acquires Edmond Pharma, API And Generics Manufacturer 56
Cobra Biologics Holding Acquires RecipharmCobra Biologics From Recipharm 57
Recipharm Completes Acquisition Of Majority Stake In Cobra Biomanufacturing 58
Recipharm Acquires Wasserburger Arzneimittelwerk 60
Recipharm AB - Key Competitors 61
Key Employees 62
Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
List of Tables
Recipharm AB, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Recipharm AB, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Recipharm AB, Deals By Therapy Area, 2010 to YTD 2016 10
Recipharm AB, Medical Devices Deals, 2010 to YTD 2016 12
Recipharm AB, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 15
Recipharm Acquires Manufacturing Site From Abbott Labs 17
Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 18
Recipharm Enters into Agreement with Follicum 19
Recipharm Enters into Agreement with Synthonics 20
Recipharm Enters Into Co-Promotion Agreement With Synthonics 21
KAHR medical Enters Into An Agreement With RecipharmCobra For KAHR-102 22
Mylan Enters Into Co-Marketing Agreement With Edmond Pharma 23
Orion Enters Into Distribution Agreement With Edmond Pharma For Erdotin 24
Alitair Pharma And Edmond Pharma Enter Into Licensing Agreement For Erdosteine 25
iNova Pharma (Australia) Enters Into Licensing Agreement With Edmond Pharma For Erdosteine 27
Life Technologies Enters Into Licensing Agreement With RecipharmCobra Biologics 29
Eddingpharm Enters Into License Agreement With Edmond Pharma For Erdotin 30
MegaPharm Enters Into Licensing Agreement With Edmond Pharma For Erdotin 31
Rottapharm Madaus Enters Into Licensing Agreement With Edmond Pharma For Mucodox 32
Recipharm to Raise up to USD104.5 Million in Rights Offering of Shares 33
Recipharm to Raise USD15.5 Million in Private Placement of Class B Shares 35
Recipharm Raises USD32 Million in Private Placement of Shares 36
Synthonics Raises USD2 Million in Private Placement of Preferred Shares 38
Flamel to Raise USD13.1 Million in Private Placement of Shares 39
Recipharm Announces Underwriters Exercise Of Over-Allotment Option Of IPO For US$131.37 Million 41
Recipharm Completes Private Placement Of Shares For US$29 Million 42
Oxford BioMedica To Acquire GMP Manufacturing Facility From Recipharm 43
Recipharm to Acquire Kemwell Biopharma 45
Recipharm Acquires 74% Stake in Nitin Lifesciences for USD101 Million 47
Recipharm Italia Acquires Mitim for USD75 Million 49
Recipharm Acquires Kaysersberg Pharma from Alcon for USD16.6 Million 50
Recipharm Acquires OnTarget Chemistry for USD1.8 Million 52
Recipharm Acquires Lusomedicameta Sociedade for USD135 Million 53
Recipharm Acquires Corvette Pharma Services from LBO Italia Investimenti for USD160 Million 54
Corvette Group Acquires Edmond Pharma, API And Generics Manufacturer 56
Cobra Biologics Holding Acquires RecipharmCobra Biologics From Recipharm 57
Recipharm Completes Acquisition Of Majority Stake In Cobra Biomanufacturing 58
Recipharm Acquires Wasserburger Arzneimittelwerk 60
Recipharm AB, Key Competitors 61
Recipharm AB, Key Employees 62
Recipharm AB, Other Locations 64
Recipharm AB, Subsidiaries 65
List of Figures
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Recipharm AB, Medical Devices Deals, 2010 to YTD 2016 12
